Ali Chegini

Ali Chegini

Auto-generated profile, based on publicly available information

Ali Chegini

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Nature
Verified
Journal Article
Closed access
PDF file
MHMohsen Hosseini
Mohsen Hosseini
VVVeronique Voisin
Veronique Voisin
ACAli Chegini
Ali Chegini
AVAngelica Varesi
Angelica Varesi
SCSeverine Cathelin
Severine Cathelin
SCSteven M. Chan
Steven M. Chan

16 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KYKira A. Young
Kira A. Young
MHMohsen Hosseini
Mohsen Hosseini
JMJayna J. Mistry
Jayna J. Mistry
CMClaudia Morganti
Claudia Morganti
TMTaylor S. Mills
Taylor S. Mills
JTJennifer J. Trowbridge
Jennifer J. Trowbridge
The competitive advantage of mutant hematopoietic stem and progenitor cells (HSPCs) underlies clonal hematopoiesis (CH). Drivers of CH include aging and inflammation; however, how CH-mutant cells gain a selective advantage in these contexts is an unresolved question. Using a murine model of CH (Dnmt3a R878H/+), we discover that mutant HSPCs sustain elevated mitochondrial respiration which is associated with their resistance to aging-related changes in the bone marrow microenvironment. Mutant HSPCs have DNA hypomethylation and increased expression of oxidative phosphorylation gene signatures, increased functional oxidative phosphorylation capacity, high mitochondrial membrane potential (Δψm), and greater dependence on mitochondrial respiration compared to wild-type HSPCs. Exploiting the elevated Δψm of mutant HSPCs, long-chain alkyl-TPP molecules (MitoQ, d-TPP) selectively accumulate in the mitochondria and cause reduced mitochondrial respiration, mitochondrial-driven apoptosis and ablate the competitive advantage of HSPCs ex vivo and in vivo in aged recipient mice. Further, MitoQ targets elevated mitochondrial respiration and the selective advantage of human DNMT3A-knockdown HSPCs, supporting species conservation. These data suggest that mitochondrial activity is a targetable mechanism by which CH-mutant HSPCs gain a selective advantage over wild-type HSPCs.

30 May 2026 in Nature Communications
Verified
Journal Article
Open access
GTGeethu Emily Thomas
Geethu Emily Thomas
VVVeronique Voisin
Veronique Voisin
KNKazem Nouri
Kazem Nouri
RHRose Hurren
Rose Hurren
KFKaren Kai-Lin Fang
Karen Kai-Lin Fang
ASAaron Schimmer
Aaron Schimmer
Eukaryotic cells have separate genomes in the nucleus and mitochondria. Mitochondrial DNA is transcribed bi-directionally to generate mitochondrial RNA (mtRNA) and dsRNA as a by-product of this transcription. We demonstrate that mtRNA transcription and degradation are increased in AML (Acute Myeloid Leukemia) cells and stem cells resulting in higher rates of mtRNA turnover. We discover that the mitochondrial degradosome, SUV3 and PNPase, is upregulated in AML cells and stem cells and functionally important for degradation of mtRNA and mitochondrial dsRNA (double stranded RNA) in AML. Depleting SUV3 or PNPase impairs mtRNA degradation and promotes the accumulation of dsRNA. dsRNA that accumulates after depleting SUV3 or PNPase, stimulates IFN-I signaling that induces AML differentiation, decreases stemness and increases sensitivity to immune-mediating cytotoxicity. Thus, this work highlights mitochondrial RNA regulation in AML and identifies a mechanism by which mtRNA turnover influences AML differentiation, stem cell function, and immune sensitization.

29 October 2026 in Cell Reports
Verified
Journal Article
Open access
GEGrace Egan
Grace Egan
AKAmit Kumar
Amit Kumar
VVVeronique Voisin
Veronique Voisin
RHRose Hurren
Rose Hurren
ACAli Chegini
Ali Chegini
ASAaron D. Schimmer
Aaron D. Schimmer